Article Information
- Received October 8, 2021
- Revision received January 11, 2022
- Accepted January 14, 2022
- Published online February 1, 2022.
Author Information
- Philip Vassilev1,2,
- Esmeralda Fonseca3,
- Giovanni Hernandez2,
- Andrea Haree Pantoja-Urban4,
- Michel Giroux2,
- Dominique Nouel3,
- Elise Van Leer2 and
- Cecilia Flores1,2
- 1Department of Psychiatry and Department of Neurology and Neurosurgery, McGill University, Montréal, QC, H3A 1A1, Canada
- 2Douglas Mental Health University Institute, Montreal, QC, H4H 1R3, Canada
- 3Princeton Neuroscience Institute, Princeton University, Princeton, NJ 08540
- 4Integrated Program in Neuroscience, McGill University, Montréal, QC, H3A 1A1, Canada
- Correspondence should be addressed to Cecilia Flores at cecilia.flores{at}mcgill.ca.
Author contributions
Author contributions: P.V., G.H., and C.F. designed research; P.V., G.H., A.H.P.-U., M.G., D.N., and E.V.L. performed research; E.F. contributed unpublished reagents/analytic tools; P.V. and E.F. analyzed data; P.V. and C.F. wrote the paper.
Disclosures
The authors declare no competing financial interests.
This work was supported by the National Institute on Drug Abuse Grant R01DA037911 (to C.F.), Canadian Institutes for Health Research Grants MOP-74709 and MOP-431097 (to C.F.), and the Natural Sciences and Engineering Research Council of Canada Grant 04703 (to C.F.). A.H.P.-U. is supported by The National Council for Science and Technology/The Consejo Nacional de Ciencia y Tecnologia (CONACYT) from México and FRQNT-Merit scholarship program for foreign students (PBEEE).
Funding
HHS | NIH | National Institute on Drug Abuse (NIDA)
R01DA037911Gouvernement du Canada | Canadian Institutes of Health Research (CIHR)
MOP-74709; MOP-431097Consejo Nacional de Ciencia y Tecnología (CONACYT)
Fonds de Recherche du Québec - Nature et Technologies (FRQNT)
Other Version
- You are viewing the most recent version of this article.
- previous version (February 01, 2022).